TY  - GEN
AU  - Tedesco,K L
AU  - Thor,A D
AU  - Johnson,D H
AU  - Shyr,Y
AU  - Blum,K A
AU  - Goldstein,L J
AU  - Gradishar,W J
AU  - Nicholson,B P
AU  - Merkel,D E
AU  - Murrey,D
AU  - Edgerton,S
AU  - Sledge,G W
TI  - Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial
SN  - 0732-183X
PY  - 2004///0408
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Disease-Free Survival
KW  - Docetaxel
KW  - Female
KW  - Gene Expression Regulation, Neoplastic
KW  - Humans
KW  - In Situ Hybridization, Fluorescence
KW  - Middle Aged
KW  - Receptor, ErbB-2
KW  - antagonists & inhibitors
KW  - Receptor, ErbB-3
KW  - Survival Analysis
KW  - Taxoids
KW  - Trastuzumab
KW  - United States
KW  - Up-Regulation
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S
UR  - https://doi.org/10.1200/JCO.2004.10.046
ER  -